Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer: A Randomized Clinical Trial.

Elit LM, Fyles AW, Gu CS, Pond GR, D'Souza D, Samant R, Anthes M, Thomas G, Filion M, Arsenault J, Dayes I, Whelan TJ, Gulenchyn KY, Metser U, Dhamanaskar K, Levine MN.

JAMA Netw Open. 2018 Sep 7;1(5):e182081. doi: 10.1001/jamanetworkopen.2018.2081.

2.

Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease.

Mc Ardle B, Shukla T, Nichol G, deKemp RA, Bernick J, Guo A, Lim SP, Davies RA, Haddad H, Duchesne L, Hendry P, Masters R, Ross H, Freeman M, Gulenchyn K, Racine N, Humen D, Benard F, Ruddy TD, Chow BJ, Mielniczuk L, DaSilva JN, Garrard L, Wells GA, Beanlands RS; PARR-2 Investigators.

Circ Cardiovasc Imaging. 2016 Sep;9(9). pii: e004331. doi: 10.1161/CIRCIMAGING.115.004331.

PMID:
27609816
3.

Characterization of 3-Dimensional PET Systems for Accurate Quantification of Myocardial Blood Flow.

Renaud JM, Yip K, Guimond J, Trottier M, Pibarot P, Turcotte E, Maguire C, Lalonde L, Gulenchyn K, Farncombe T, Wisenberg G, Moody J, Lee B, Port SC, Turkington TG, Beanlands RS, deKemp RA.

J Nucl Med. 2017 Jan;58(1):103-109. doi: 10.2967/jnumed.116.174565. Epub 2016 Aug 18.

4.

Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial.

Serrano PE, Gafni A, Gu CS, Gulenchyn KY, Julian JA, Law C, Hendler AL, Moulton CA, Gallinger S, Levine MN.

J Oncol Pract. 2016 Jul;12(7):e765-74. doi: 10.1200/JOP.2016.011676. Epub 2016 Jun 21.

PMID:
27328792
5.

Imaging Biomarkers in Immunotherapy.

Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY.

Biomark Cancer. 2016 Feb 25;8(Suppl 2):1-13. doi: 10.4137/BIC.S31805. eCollection 2016. Review.

6.

Biological Response of Positron Emission Tomography Scan Exposure and Adaptive Response in Humans.

Schnarr K, Carter TF, Gillis D, Webber C, Lemon JA, Dayes I, Dolling JA, Gulenchyn K, Boreham DR.

Dose Response. 2015 Nov 19;13(4):1559325815611904. doi: 10.1177/1559325815611904. eCollection 2015 Oct-Dec.

7.

Effectiveness of Quality Improvement Interventions at Reducing Inappropriate Cardiac Imaging: A Systematic Review and Meta-Analysis.

Chaudhuri D, Montgomery A, Gulenchyn K, Mitchell M, Joseph P.

Circ Cardiovasc Qual Outcomes. 2016 Jan;9(1):7-13. doi: 10.1161/CIRCOUTCOMES.115.001836. Epub 2016 Jan 5. Review.

PMID:
26733588
8.

(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.

You JJ, Cline KJ, Gu CS, Pritchard KI, Dayes IS, Gulenchyn KY, Inculet RI, Dhesy-Thind SK, Freeman MA, Chan AM, Julian JA, Levine MN.

Br J Cancer. 2015 May 26;112(11):1737-43. doi: 10.1038/bjc.2015.151. Epub 2015 May 5.

9.

Positron Emission Tomography for Nine Cancers (Bladder, Brain, Cervical, Kidney, Ovarian, Pancreatic, Prostate, Small Cell Lung, Testicular) [Internet].

Ospina MB, Horton J, Seida J, Vandermeer B, Liang G, McEwan AJ, Gulenchyn K.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Dec 1.

10.

PET screening for metastatic colorectal adenocarcinoma--reply.

Moulton CA, Gulenchyn K, Levine MN.

JAMA. 2014 Sep 24;312(12):1256-7. doi: 10.1001/jama.2014.9853. No abstract available.

PMID:
25247525
11.

Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial.

Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith RJ, Jalink DW, Husien M, Serrano PE, Hendler AL, Haider MA, Ruo L, Gulenchyn KY, Finch T, Julian JA, Levine MN, Gallinger S.

JAMA. 2014 May 14;311(18):1863-9. doi: 10.1001/jama.2014.3740.

PMID:
24825641
12.

Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.

You JJ, Wong RK, Darling G, Gulenchyn K, Urbain JL, Evans WK.

J Thorac Oncol. 2013 Dec;8(12):1563-9. doi: 10.1097/JTO.0000000000000006.

13.

Clinical interpretation standards and quality assurance for the multicenter PET/CT trial rubidium-ARMI.

Renaud JM, Mylonas I, McArdle B, Dowsley T, Yip K, Turcotte E, Guimond J, Trottier M, Pibarot P, Maguire C, Lalonde L, Gulenchyn K, Wisenberg G, Wells RG, Ruddy T, Chow B, Beanlands RS, deKemp RA.

J Nucl Med. 2014 Jan;55(1):58-64. doi: 10.2967/jnumed.112.117515. Epub 2013 Nov 18.

14.

Vertebral fracture prevalence in a referral population of 750 Canadian men and women.

Yakemchuk V, Beaumont LF, Webber CE, Gulenchyn KY, Jager PL.

Clin Radiol. 2012 Nov;67(11):1061-8. doi: 10.1016/j.crad.2012.02.011. Epub 2012 Sep 5.

PMID:
22959172
15.

Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.

Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, Hodgson N, Lovrics P, Perera F, Elavathil L, O'Malley FP, Down N, Bodurtha A, Shelley W, Levine MN.

J Clin Oncol. 2012 Apr 20;30(12):1274-9. doi: 10.1200/JCO.2011.38.1103. Epub 2012 Mar 5.

PMID:
22393089
16.

The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience.

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, Gulenchyn KY, Dekemp RA, Dasilva J, Birnie D, Wells GA, Beanlands RS.

J Nucl Med. 2012 Feb;53(2):241-8. doi: 10.2967/jnumed.111.090662. Epub 2012 Jan 6. Review.

17.

Radionuclide therapy in neuroendocrine tumours: a systematic review.

Gulenchyn KY, Yao X, Asa SL, Singh S, Law C.

Clin Oncol (R Coll Radiol). 2012 May;24(4):294-308. doi: 10.1016/j.clon.2011.12.003. Epub 2012 Jan 4. Review.

PMID:
22221516
18.

PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.

Yakemchuk VN, Jager PL, Chirakal R, Reid R, Major P, Gulenchyn KY.

Nucl Med Commun. 2012 Mar;33(3):322-30. doi: 10.1097/MNM.0b013e32834f2603.

PMID:
22183015
19.

Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial.

Shukla T, Nichol G, Wells G, deKemp RA, Davies RA, Haddad H, Duchesne L, Freeman M, Gulenchyn K, Racine N, Humen D, Benard F, Ruddy TD, Chow BJ, DaSilva J, Garrard L, Guo A, Chen L, Beanlands RS.

Can J Cardiol. 2012 Jan-Feb;28(1):54-61. doi: 10.1016/j.cjca.2011.09.012. Epub 2011 Dec 3.

PMID:
22138342
20.

Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.

Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Gu CS, Kuruvilla MS, Cline KJ, Julian JA, Evans WK, Levine MN.

J Thorac Oncol. 2011 Aug;6(8):1367-72. doi: 10.1097/JTO.0b013e318220c912. Erratum in: J Thorac Oncol. 2012 Mar;7(3):628.

21.

Radiation doses originating from diagnostic procedures during the treatment and follow-up of children and adolescents with malignant lymphoma.

Pierobon J, Webber CE, Nayiager T, Barr RD, Moran GR, Gulenchyn KY.

J Radiol Prot. 2011 Mar;31(1):83-93. doi: 10.1088/0952-4746/31/1/005. Epub 2011 Feb 23.

PMID:
21346283
22.

Combined vertebral fracture assessment and bone mineral density measurement: a patient-friendly new tool with an important impact on the Canadian Risk Fracture Classification.

Jager PL, Slart RH, Webber CL, Adachi JD, Papaioannou AL, Gulenchyn KY.

Can Assoc Radiol J. 2010 Oct;61(4):194-200. doi: 10.1016/j.carj.2009.12.012. Epub 2010 Mar 4.

23.

Is a fixed value for the least significant change appropriate?

Nelson L, Gulenchyn KY, Atthey M, Webber CE.

J Clin Densitom. 2010 Jan-Mar;13(1):18-23. doi: 10.1016/j.jocd.2009.10.001.

PMID:
20171565
24.

Evidence-based approach to the introduction of positron emission tomography in ontario, Canada.

Evans WK, Laupacis A, Gulenchyn KY, Levin L, Levine M.

J Clin Oncol. 2009 Nov 20;27(33):5607-13. doi: 10.1200/JCO.2009.22.1614. Epub 2009 Oct 26. Review.

PMID:
19858395
25.

Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial.

D'Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, Ruddy TD, DaSilva J, Humen D, Gulenchyn KY, Freeman M, Racine N, Benard F, Hendry P, Beanlands RS; PARR-2 Investigators.

JACC Cardiovasc Imaging. 2009 Sep;2(9):1060-8. doi: 10.1016/j.jcmg.2009.02.017.

26.

Positron emission tomography in staging early lung cancer: a randomized trial.

Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu CS, Cline KJ, Evans WK, Levine MN.

Ann Intern Med. 2009 Aug 18;151(4):221-8, W-48. Epub 2009 Jul 6.

PMID:
19581636
27.

Is Thyroid Screening Necessary for Nuclear Medicine Personnel Receiving and Administering Capsules Containing Large Doses of 131I?

Gulenchyn KY, Webber CE.

J Med Imaging Radiat Sci. 2009 Jun;40(2):60-63. doi: 10.1016/j.jmir.2009.03.003. Epub 2009 Jun 3.

PMID:
31051874
28.

6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications.

Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY.

J Nucl Med. 2008 Apr;49(4):573-86. doi: 10.2967/jnumed.107.045708. Epub 2008 Mar 14. Review.

29.

Is there a role for positron emission tomography in breast cancer staging?

Hodgson NC, Gulenchyn KY.

J Clin Oncol. 2008 Feb 10;26(5):712-20. doi: 10.1200/JCO.2007.13.8412. Review.

PMID:
18258978
30.

18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.

Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

J Natl Cancer Inst. 2007 Dec 5;99(23):1753-67. Epub 2007 Nov 27. Review.

PMID:
18042932
31.

F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).

Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM; PARR-2 Investigators.

J Am Coll Cardiol. 2007 Nov 13;50(20):2002-12. Epub 2007 Oct 10.

32.

CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease--executive summary.

Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, Kiess M, Leong-Poi H, Miller RM, Nichol G, Freeman M, Bogaty P, Honos G, Hudon G, Wisenberg G, Van Berkom J, Williams K, Yoshinaga K, Graham J; Canadian Cardiovascular Society; Canadian Association of Radiologists; Canadian Association of Nuclear Medicine; Canadian Nuclear Cardiology Society; Canadian Society of Cardiac Magnetic Resonance.

Can J Cardiol. 2007 Feb;23(2):107-19.

33.

Treating the right patient at the right time: access to cardiovascular nuclear imaging.

Gulenchyn KY, McEwan AJ, Freeman M, Kiess M, O'Neill BJ, Beanlands RS; CANM; CSS.

Can J Cardiol. 2006 Aug;22(10):827-33.

34.

Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.

Marriott CJ, Webber CE, Gulenchyn KY.

Radiat Prot Dosimetry. 2007;123(1):62-7. Epub 2006 Jul 6.

PMID:
16825250
35.

Influence of bone densitometry results on the treatment of osteoporosis.

Fitt NS, Mitchell SL, Cranney A, Gulenchyn K, Huang M, Tugwell P.

CMAJ. 2001 Mar 20;164(6):777-81.

36.

"Double chamber" right ventricle due to prominent trabeculation.

Choong KK, Ruddy TD, Ascah KJ, Gulenchyn KY.

Clin Nucl Med. 1995 Sep;20(9):830-1. No abstract available.

PMID:
8521663
37.

'Vascular scalp lesion' from cardiac activity.

Choong KK, Gulenchyn KY, Chamberlain MJ.

Clin Nucl Med. 1994 Aug;19(8):744-5. No abstract available.

PMID:
7955762
38.

Cardiac risk stratification using dipyridamole myocardial perfusion imaging and ambulatory ECG monitoring prior to vascular surgery.

McPhail NV, Ruddy TD, Barber GG, Cole CW, Marois LJ, Gulenchyn KY.

Eur J Vasc Surg. 1993 Mar;7(2):151-5.

PMID:
8462703
39.

Cerebral perfusion imaging with technetium-99m HMPAO following cerebral trauma. Initial experience.

Reid RH, Gulenchyn KY, Ballinger JR, Ventureyra EC.

Clin Nucl Med. 1990 Jun;15(6):383-8.

PMID:
2354575
40.

Comparison of left ventricular function and myocardial perfusion for evaluating perioperative cardiac risk of abdominal aortic surgery.

McPhail NV, Ruddy TD, Calvin JE, Barber GG, Cole CW, Davies RA, Gulenchyn KY.

Can J Surg. 1990 Jun;33(3):224-8.

PMID:
2350747
41.

A kit for labelling erythrocytes or leukocytes with technetium-99m.

Proulx A, Gerson B, Ballinger JR, Gulenchyn KY.

Int J Rad Appl Instrum B. 1990;17(5):515-7.

PMID:
2391248
42.

Effect of granulocyte concentration on leukocyte labelling efficiency with 99mTc-HMPAO.

Ballinger JR, Proulx A, Gerson B, Gulenchyn KY.

Int J Rad Appl Instrum B. 1990;17(4):443. No abstract available.

PMID:
2387752
43.

In vitro comparison of HMPAO and gentisic acid for labelling leukocytes with 99mTc.

Ecclestone M, Proulx A, Ballinger JR, Gerson B, Reid RH, Gulenchyn KY.

Eur J Nucl Med. 1990;16(4-6):299-302.

PMID:
2161770
44.

Radiopharmaceutical factors in the variable quality of [99mTc]HM-PAO images of the brain.

Ballinger JR, Gulenchyn KY, Reid RH.

J Nucl Med. 1990 Jan;31(1):118-22.

45.

Clinical use of technetium-99m HM-PAO for determination of brain death.

Reid RH, Gulenchyn KY, Ballinger JR.

J Nucl Med. 1989 Oct;30(10):1621-6.

46.

Technetium-99m dithiocarbamates as potential brain agents: evaluation of aliphatic and amine-containing analogues.

Ballinger JR, Gerson B, Gulenchyn KY.

Int J Rad Appl Instrum B. 1989;16(7):721-5.

PMID:
2613528
47.

Technetium-99m spiperone dithiocarbamate: a potential radiopharmaceutical for dopamine receptor imaging with SPECT.

Ballinger JR, Gulenchyn KY, Hassan MN.

Int J Rad Appl Instrum A. 1989;40(6):547-9.

PMID:
2551854
48.

Routine determination of radiochemical purity of 99mTc-MIBI.

Proulx A, Ballinger JR, Gulenchyn KY.

Int J Rad Appl Instrum A. 1989;40(1):95-7.

PMID:
2540127
49.

Technetium-99m HM-PAO stereoisomers: differences in interaction with glutathione.

Ballinger JR, Reid RH, Gulenchyn KY.

J Nucl Med. 1988 Dec;29(12):1998-2000.

50.

Radiochemical purity of [99mTc]HM-PAO.

Ballinger JR, Reid RH, Gulenchyn KY.

J Nucl Med. 1988 Apr;29(4):572-3. No abstract available.

Supplemental Content

Loading ...
Support Center